Response comparison of multiple myeloma and monoclonal gammopathy of undetermined significance to the same anti-myeloma therapy

The Lancet Haematology

Published: 13 November 2017

DOI: http://dx.doi.org/10.1016/S2352-3026(17)30209-0

John P Campbell, PhD, Jennifer L J Heaney, PhD, Sankalp Pandya, MRes, Zaheer Afzal, MSc, Martin Kaiser, MD, Roger Owen, MD, Prof J Anthony Child, MD, David A Cairns, PhD, Prof Walter Gregory, PhD, Prof Gareth J Morgan, MD, ProfGraham H Jackson, MD, Prof Chris M Bunce, PhD, Prof Mark T Drayson, MD

Background: Multiple myeloma is consistently preceded by monoclonal gammopathy of undetermined significance (MGUS), which is usually only treated by a form of anti-multiple myeloma therapy if it is causing substantial disease through deposition of secreted M proteins. However, studies comparing how MGUS and multiple myeloma plasma cell clones respond to these therapies are scarce. 

SEGUIR LEYENDO